A Nutritional Metabolism Related Prognostic Scoring System for Patients With Newly Diagnosed Osteosarcoma

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2022 May 16

PMID 35571914

Authors

Longqing Li

Zhuangzhuang Li

Xuanhong He

Yang Wang

Minxun Lu

Taojun Gong

Qing Chang

Jingqi Lin

Yi Luo

Li Min

Yong Zhou

Chongqi Tu

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma is a primary malignant bone tumor with high metastatic potential. To date, achieving long-term survival of osteosarcoma patients remains a difficult task. Metabolic reprogramming has emerged as a new hallmark of cancer. However, studies on the prognostic value of hematological markers related to nutritional and metabolism in cancer patients are limited and contradictory. In this retrospective study, we extensively collected 16 hematological markers related to nutritional and metabolism in 223 osteosarcoma patients. A nutritional metabolism related prognostic scoring system (NMRS) in patients with osteosarcoma was constructed by least absolute contraction and selection operator (LASSO) cox regression analysis. Compared with individual hematological indicators, NMRS has stronger predictive power (training set: 0.811 vs. 0.362-2.638; validation set: 0.767 vs. 0.333-0.595). It is an independent prognostic factor for the survival of patients with osteosarcoma [HR: 1.957 (1.375-2.786) training set; HR: 3.146 (1.574-6.266) validation set]. NMRS-based nomograms have good and stable predictive power. NMRS facilitates further risk stratification of patients with the same clinical characteristics.

Citing Articles

Unveiling the prognostic implications of RPLP1 upregulation in osteosarcoma.

Du X, Wei H, Zhang B, Pang L, Zhao R, Zhang X Am J Cancer Res. 2023; 13(10):4822-4831.

PMID: 37970363 PMC: 10636679.

Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities.

Du X, Wei H, Zhang B, Wang B, Li Z, Pang L Front Oncol. 2023; 13:1117867.

PMID: 37197432 PMC: 10183593. DOI: 10.3389/fonc.2023.1117867.

N1-methyladenosine methylation-related metabolic genes signature and subtypes for predicting prognosis and immune microenvironment in osteosarcoma.

Wang G, Wang H, Cheng S, Zhang X, Feng W, Zhang P Front Genet. 2022; 13:993594.

PMID: 36147503 PMC: 9485621. DOI: 10.3389/fgene.2022.993594.

References

Ryu T, Park J, Scherer P . Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014; 38(5):330-6. PMC: 4209346. DOI: 10.4093/dmj.2014.38.5.330. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Hao B, Bi B, Sang C, Yu M, Di D, Luo G . Systematic Review and Meta-Analysis of the Prognostic Value of Serum High-Density Lipoprotein Cholesterol Levels for Solid Tumors. Nutr Cancer. 2019; 71(4):547-556. DOI: 10.1080/01635581.2019.1577983. View

Kager L, Tamamyan G, Bielack S . Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2016; 13(4):357-368. DOI: 10.2217/fon-2016-0261. View

Meyers P, Schwartz C, Krailo M, Kleinerman E, Betcher D, Bernstein M . Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23(9):2004-11. DOI: 10.1200/JCO.2005.06.031. View

Patel N, Vogel R, Chandra-Kuntal K, Glasgow W, Kelavkar U . A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer. PLoS One. 2014; 9(3):e88841. PMC: 3945968. DOI: 10.1371/journal.pone.0088841. View

Whelan J, Davis L . Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol. 2017; 36(2):188-193. DOI: 10.1200/JCO.2017.75.1743. View

Forrest S, Geoerger B, Janeway K . Precision medicine in pediatric oncology. Curr Opin Pediatr. 2017; 30(1):17-24. PMC: 5770114. DOI: 10.1097/MOP.0000000000000570. View

Kempf-Bielack B, Bielack S, Jurgens H, Branscheid D, Berdel W, Exner G . Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005; 23(3):559-68. DOI: 10.1200/JCO.2005.04.063. View

10.

Wu N, Chen G, Hu H, Pang L, Chen Z . Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas. Nutr Cancer. 2015; 67(3):481-5. DOI: 10.1080/01635581.2015.1004726. View

11.

Visweswaran M, Arfuso F, Warrier S, Dharmarajan A . Aberrant lipid metabolism as an emerging therapeutic strategy to target cancer stem cells. Stem Cells. 2019; 38(1):6-14. DOI: 10.1002/stem.3101. View

12.

Cupp M, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor A . Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020; 18(1):360. PMC: 7678319. DOI: 10.1186/s12916-020-01817-1. View

13.

Kamphorst J, Nofal M, Commisso C, Hackett S, Lu W, Grabocka E . Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015; 75(3):544-53. PMC: 4316379. DOI: 10.1158/0008-5472.CAN-14-2211. View

14.

Li L, Bai Z, Zhang L, Zhang Y, Lu X, Zhang Y . Meta-Analysis of Hematological Biomarkers as Reliable Indicators of Soft Tissue Sarcoma Prognosis. Front Oncol. 2020; 10:30. PMC: 7002470. DOI: 10.3389/fonc.2020.00030. View

15.

Ramteke P, Deb A, Shepal V, Bhat M . Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality. Cancers (Basel). 2019; 11(9). PMC: 6770430. DOI: 10.3390/cancers11091402. View

16.

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

17.

Hong X, Sullivan R, Kalinich M, Kwan T, Giobbie-Hurder A, Pan S . Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018; 115(10):2467-2472. PMC: 5877960. DOI: 10.1073/pnas.1719264115. View

18.

Flint T, Janowitz T, Connell C, Roberts E, Denton A, Coll A . Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab. 2016; 24(5):672-684. PMC: 5106372. DOI: 10.1016/j.cmet.2016.10.010. View

19.

Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A . Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293. PMC: 7736102. DOI: 10.1016/j.addr.2020.07.013. View

20.

Xie H, Zhang Q, Ruan G, Ge Y, Hu C, Song M . Evaluation and Validation of the Prognostic Value of Serum Albumin to Globulin Ratio in Patients With Cancer Cachexia: Results From a Large Multicenter Collaboration. Front Oncol. 2021; 11:707705. PMC: 8461248. DOI: 10.3389/fonc.2021.707705. View